CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


IvermectinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (39)


Name (Synonyms) Correlation
drug560 Chloroquine Wiki 0.25
drug2794 current IPAC-UHN PPE Wiki 0.24
drug173 Angiotensin II Wiki 0.24
drug1708 Other drugs Wiki 0.24
drug2350 Standard treatment for COVID-19 Wiki 0.24
drug2870 liposomal lactoferrin Wiki 0.24
drug2921 non interventional Wiki 0.24
drug1229 Interleukin-1 receptor antagonist Wiki 0.24
drug212 Artemesia annua Wiki 0.24
drug2202 Sars-Cov-2 serology Wiki 0.24
drug385 Blood samples collection Wiki 0.24
drug352 Biological test Wiki 0.24
drug2109 Robot Assisted Percutaneous Cardiovascular Intervention Wiki 0.24
drug570 Cholecalciferol Wiki 0.24
drug2859 iota carrageenan Wiki 0.24
drug1603 Nitazoxanide with ivermectin Wiki 0.24
drug1423 Machine learning model Wiki 0.24
drug1935 Proxalutamide Wiki 0.24
drug2896 modified IPAC-UHN PPE Wiki 0.24
drug1889 Powered Air purifying respirator Wiki 0.24
drug799 Dutasteride Wiki 0.24
drug1283 Ivermectin wth chloroquine Wiki 0.24
drug2004 RO6953958 Wiki 0.24
drug1592 Niclosamide Wiki 0.17
drug652 Convalescent Plasma Transfusion Wiki 0.17
drug1598 Nitazoxanide Wiki 0.17
drug1117 Hydroxychloroquine and Azithromycin Wiki 0.17
drug285 BCG vaccine Wiki 0.14
drug290 BI 894999 Wiki 0.14
drug262 Azithromycin Wiki 0.12
drug1219 Interferon Beta-1A Wiki 0.12
drug791 Doxycycline Wiki 0.12
drug2187 Saliva collection Wiki 0.11
drug512 Camostat Mesilate Wiki 0.11
drug698 DAS181 Wiki 0.10
drug1822 Placebo Wiki 0.09
drug1374 Losartan Wiki 0.08
drug1086 Hydroxychloroquine Wiki 0.07
drug923 Favipiravir Wiki 0.06

Correlated MeSH Terms (30)


Name (Synonyms) Correlation
D010146 Pain NIH 0.24
D011470 Prostatic Hyperplasia NIH 0.24
D006965 Hyperplasia NIH 0.24
D002658 Developmental Disabilities NIH 0.24
D001416 Back Pain NIH 0.24
D003327 Coronary Disease NIH 0.24
D017116 Low Back Pain NIH 0.24
D011001 Pleuropneumonia NIH 0.24
D065886 Neurodevelopmental Disorders NIH 0.17
D000505 Alopecia NIH 0.17
D002659 Child Development Disorders, Pervasive NIH 0.14
D001321 Autistic Disorder NIH 0.12
D006331 Heart Diseases NIH 0.12
D003324 Coronary Artery Disease NIH 0.12
D045169 Severe Acute Respiratory Syndrome NIH 0.11
D018352 Coronavirus Infections NIH 0.11
D002277 Carcinoma NIH 0.11
D000067877 Autism Spectrum Disorder NIH 0.10
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.08
D009203 Myocardial Ischemia NIH 0.08
D008173 Lung Diseases, Obstructive NIH 0.08
D007239 Infection NIH 0.07
D013577 Syndrome NIH 0.05
D001523 Mental Disorders NIH 0.05
D055371 Acute Lung Injury NIH 0.05
D012127 Respiratory Distress Syndrome, Newborn NIH 0.05
D004194 Disease NIH 0.04
D012128 Respiratory Distress Syndrome, Adult NIH 0.04
D014777 Virus Diseases NIH 0.03
D003141 Communicable Diseases NIH 0.02

Correlated HPO Terms (12)


Name (Synonyms) Correlation
HP:0003418 Back pain HPO 0.24
HP:0008711 Benign prostatic hyperplasia HPO 0.24
HP:0012531 Pain HPO 0.24
HP:0003419 Low back pain HPO 0.24
HP:0002293 Alopecia of scalp HPO 0.17
HP:0001677 Coronary artery atherosclerosis HPO 0.12
HP:0000717 Autism HPO 0.12
HP:0030731 Carcinoma HPO 0.11
HP:0000729 Autistic behavior HPO 0.10
HP:0001658 Myocardial infarction HPO 0.08
HP:0006510 Chronic pulmonary obstruction HPO 0.08
HP:0006536 Pulmonary obstruction HPO 0.08

There are 18 clinical trials

Clinical Trials


1 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19

COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.

NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs

Primary Outcomes

Description: the estimated number of patients with decreased viral load

Measure: Number of patients with decreased viral load

Time: 6 months

2 Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment

Efficacy of Ivermectin and Nitazoxanide in COVID-19 treatment

NCT04351347 COVID Drug: Ivermectin Drug: Nitazoxanide with ivermectin Drug: Ivermectin wth chloroquine

Primary Outcomes

Description: The number of patients with improvement or death

Measure: Number of patients with improvement or died

Time: 1 month

3 To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study

At present, there are no specific treatments for COVID-19. WHO recommends four treatments for COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon beta -1a, and chloroquine or hydroxychloroquine. Currently, there are several ongoing clinical trials evaluating potential treatments. Recently, LeonCaly reported that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARSCoV-2 able to effect about 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrant further investigation for possible benefits in humans. The study rationale is to understand the effect of the drug on eradication of virus.

NCT04373824 COVID Drug: Ivermectin

Primary Outcomes

Description: Test for virus at 1, 3 & 5 days from beginning of trial drug started for the patient in the hospital

Measure: effect of Ivermectin on eradication of virus.

Time: 3 months

4 Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients

This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.

NCT04374019 COVID Sars-CoV2 Drug: Hydroxychloroquine and Azithromycin Drug: Ivermectin Drug: Camostat Mesilate Dietary Supplement: Artemesia annua

Primary Outcomes

Description: Proportion of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes.

Measure: Clinical Deterioration

Time: 14 days

Secondary Outcomes

Description: The change in (clearance of) viral RNA will be measured by PCR testing at days 1, 14, 28, and 40 days.

Measure: Change in Viral Load

Time: 40 days

Description: Percentage of patients that experience severe respiratory or other organ failure.

Measure: Rate of Organ Failure

Time: 28 days

Description: Percentage of patients requiring ICU admission or ventilation.

Measure: Progression to ICU Care or Ventilation

Time: 28 days

Description: Clinical status will be assessed using the COVID 7-Point Ordinal Outcomes Scale. This scale ranges from 1-7. Lower scores indicate worse outcomes; higher scores indicate fewer symptoms and better outcomes.

Measure: Change in Clinical Status

Time: 14 days

Description: Percentage of patients who have died by day 14.

Measure: Mortality

Time: 14 days

Description: Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events.

Measure: Rate of severe adverse events

Time: 14 days

Description: Number of days patients do not require oxygen supplementation.

Measure: Oxygen-free days

Time: 28 days

Description: Number of days patients do not require mechanical ventilation.

Measure: Ventilator-free days

Time: 28 days

Description: Number of days patients do not require vasopressor treatment.

Measure: Vasopressor-free days

Time: 28 days

Description: Number of days patients do not require ICU services.

Measure: ICU-free days

Time: 28 days

Description: Number of days patients do not require hospitalization.

Measure: Hospital-free days

Time: 28 days

Description: Proportion of patients meeting Hy's law criteria.

Measure: Patients meeting Hy's Law criteria

Time: 28 days

Description: Proportion of patients with changes in the following liver function tests: Any ALT or AST ≥ 5 x ULN; any AST or ALT ≥ 3 x ULN together with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (eosinophil percent or count above the ULN); Persistent ALT ≥ 3 x ULN for a period of more than 4 weeks

Measure: Liver Function

Time: 28 days

Description: Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of > 500 ms.

Measure: Heart Function

Time: 28 days

5 Novel Treatment Regimens in Treatment of COVID-19

Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

NCT04382846 COVID Corona Virus Infection Drug: Nitazoxanide Drug: Ivermectin Drug: Chloroquine Drug: Azithromycin
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: the number of patients with virological cure

Measure: Number of patients with virological cure

Time: 6 months

6 Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission

SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial is currently planned at a single center in Navarra.

NCT04390022 Covid-19 Coronavirus Infection SARS-CoV-2 Infection Drug: Ivermectin Drug: Placebo
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment

Measure: Proportion of patients with a positive SARS-CoV-2 PCR

Time: 7 days post-treatment

Secondary Outcomes

Description: Change from baseline quantitative and semi-quantitative PCR in nasopharyngeal swab

Measure: Mean viral load

Time: Baseline and on days 4, 7, 14 and 21

Description: Proportion of patients with fever and cough at days 4, 7, 14 and 21 as well as proportion of patients progressing to severe disease or death during the trial

Measure: Fever and cough progression

Time: Up to and including day 21

Description: Proportion of participants with positive IgG at day 21

Measure: Seroconversion at day 21

Time: Up to and including day 21

Description: Proportion of drug-related adverse events

Measure: Proportion of drug-related adverse events

Time: 7 days post treatment

Description: Levels in median fluorescence intensity (MFI) of IgG, IgM and IgA against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 in plasma, measured by a Luminex assay

Measure: Levels of IgG, IgM and IgA

Time: Up to and including day 28

Description: Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry

Measure: Frequency of innate immune cells

Time: Up to and including day 7

Description: Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry

Measure: Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells

Time: Up to and including day 7

Description: Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher)

Measure: Results from cytokine Human Magnetic 30-Plex Panel

Time: Up to and including day 28

7 Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial

Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world. In February 2020, the WHO declared a pandemic. Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. At this time there is no proven therapeutic alternative. In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and hydroxychloroquine) had antiviral activity and increased viral clearance. Ivermectin, on the other hand, has been shown in vitro to reduce viral replication and in an observational cohort, greater viral clearance with promising clinical results. So far there is no standard of treatment and clinical trials are needed to find effective treatment alternatives. Objective: To evaluate the safety and efficacy of treatment with hydroxychloroquine and ivermectin for serious COVID-19 infections in no critical hospitalized patients. Material and methods: Randomized controlled trial of patients diagnosed with respiratory infection by COVID-19, who present criteria for hospitalization. Randomization will be performed to receive hydroxychloroquine at a dose of 400 mg every 12 hours for one day and then 200 mg every 12 hours, to complete a 5-day treatment schedule. Group 2: Ivermectin 12 mg every 24 hours for one day (less than 80 kg) or Ivermectin 18 mg every 24 hours for one day (greater than 80 kg) + placebo until the fifth day. Group 3: Placebo. Prior to randomization, the risk of cardiovascular complications determined by corrected QT interval, related to hydroxychloroquine intake will be assessed. If the patient is at high risk, the allocation will be to ivermectin only or to placebo in an independent randomization, if the risk is low, any of the three groups could be assigned. Outcomes: The primary outcome will be discharge from hospital for improvement. The safety outcomes will be requirement of mechanical intubation, septic shock or death. Viral clearance will also be evaluated by means of PCR, which will be taken on the 5th day after admission, day 14 and 21.

NCT04391127 COVID-19 Drug: Hydroxychloroquine Drug: Ivermectin Drug: Placebo
MeSH:Infection

Primary Outcomes

Description: Days from admission as a suspected case of COVID with hospitalization criteria until discharge

Measure: Mean days of hospital stay

Time: Three months

Description: Respiratory deterioration defined by respiratory rate > 25 per minute, requirement of high oxygen supply (FiO2 > 80% ) to maintain oxygen saturation > 90 %, invasive mechanical ventilation or dead.

Measure: Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead

Time: Three months

Description: Daily delta of oxygenation index during the hospitalization

Measure: Mean of oxygenation index delta

Time: Three months

Secondary Outcomes

Description: Mean time to viral negativization of RT-qPCR SARS-CoV-2. Pre Specified time: 5, 14, 21 and 28 days after the first positive PCR.

Measure: Mean time to viral PCR negativization

Time: 5, 14, 21 and 28 days after the first positive PCR

8 A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol

As the world faces COVID-19, the search for effective treatments against the disease and its complications has turned its gaze to drugs that are classically used in other infectious diseases. Some drugs are being examined for the recent evidence on its effects on viral replication and inflammation, one is Azithromycin, used to treat a wide variety of bacterial infections, Ivermectin, an anti-parasitic drug and the other is Cholecalciferol to increase serum concentration of 25-hydroxyvitamin D.

NCT04399746 COVID Drug: Ivermectin Drug: Azithromycin Drug: Cholecalciferol

Primary Outcomes

Description: Test for virus at day 1 and 14 from beginning of trial drug started

Measure: Viral clearance

Time: 14 days

Secondary Outcomes

Description: The duration of symptoms in days

Measure: Symptoms duration

Time: 14 days

Description: oxygen saturation

Measure: SpO2

Time: 14 days

Description: Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) Ratio

Measure: SpO2/FiO2

Time: 14 days

9 The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment

Efficacy of Ivermectin and Doxycycline in COVID-19 treatment

NCT04403555 COVID Drug: Ivermectin Drug: Doxycycline Drug: Chloroquine

Primary Outcomes

Description: The number of patients with improvement or mortality

Measure: The number of patients with improvement or mortality

Time: 1 month

10 Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms

This study aims to evaluate the efficacy, safety and tolerability of Ivermectin in patients with mild SARS-CoV-2 infection, in the rate of progression to severe 2019 novel coronavirus disease (COVID-19). The primary efficacy endpoint is the proportion of participants with a disease control status defined as no progression of severe disease Hypothesis (H0): There is no difference between group A (ivermectin + paracetamol) and group B (ivermectin + paracetamol) in terms of the primary endpoint on day 14.

NCT04407507 COVID-19 Drug: Ivermectin Drug: Placebo

Primary Outcomes

Description: The subject is considered to have progressed to severe illness when one or more of the following criteria are present: Breathing difficulty (≥30 breaths per minute); Resting oxygen saturation ≤93%; Severe complications such as: respiratory failure, need for mechanical ventilation, septic shock, non-respiratory organic failure.

Measure: Participants with a disease control status defined as no disease progression to severe.

Time: 14 days

11 The Use of Ivermectin In the Treatment of COVID 19 Patients

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

NCT04425707 Covid19 Drug: Ivermectin

Primary Outcomes

Description: the role of ivermectin in the cure of COVID 19 patients

Measure: to evaluate the role of Ivermectin as a line of treatment for COVID 19

Time: 2 months

Secondary Outcomes

Description: to compare the results of ivermectin with the standard care

Measure: To asses the rate of viral clearance in comparison to other treatment protocols.

Time: 2 months

12 USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel

Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease. It is estimated that 86% of all infections were undocumented [95% credible interval (CI): 82-90%] before the 23 January 2020 travel restrictions. The transmission rate of undocumented infections per person was 55% the transmission rate of documented infections (95% CI: 46-62%), yet, because of their greater numbers, undocumented infections were the source of 79% of the documented cases. Ivermectin + Carrageenan, taking advantage of their virucidal effects, are aimed at reducing the contagion.

NCT04425850 Contagious Pleuropneumonia Device: iota carrageenan Drug: Ivermectin
MeSH:Pleuropneumonia, Contagious Pleuropneumonia

Primary Outcomes

Description: For Health Personnel, the average dessertion all over the world has raised to 27 % worldwide. We aim at reducing it dramaticaly.

Measure: Reduction in contagion

Time: 30 days

Secondary Outcomes

Description: Allergy to any of the two drugs administered topically

Measure: Secondary and or side effects

Time: 7 days

13 Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)

In December 2019, a group of patients with pneumonia of unknown cause was linked to a wholesale seafood market in Wuhan, China. The genetic analysis of samples from the lower respiratory tract of these patients indicated a new coronavirus as the causative agent, which was named SARS-CoV-2. The virus spread rapidly to more than 45 countries, including Brazil, causing an international alarm. However, in spite of its epidemiological magnitude, so far, there is no antiviral treatment or vaccine approved for the treatment of this infection. With about 15% to 20% of SARS-CoV-2 patients suffering from serious illnesses and overburdened hospitals, therapeutic options are desperately needed. So, instead of creating compounds from scratch that can take years to develop and test, researchers and public health agencies have sought to redirect drugs already approved for other diseases and known to be widely safe. In this context, the analysis of the international literature shows the existence of an in vitro antiviral activity of ivermectin against SARS-CoV-2. However, there are no studies that have evaluated its clinical effectiveness in patients diagnosed with SARS-CoV-2 infection. Therefore, and considering this knowledge gap, the present study aims to determine the clinical efficacy and safety of different doses of ivermectin in patients diagnosed with SARS-CoV-2 infection.

NCT04431466 Coronavirus Infection Drug: Ivermectin Other: Standard treatment for COVID-19
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab after Intervention Initiation.

Measure: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.

Time: 7 days following intervention

Secondary Outcomes

Description: Viral load variation in the nasopharyngeal swab during treatment.

Measure: Viral load variation in the nasopharyngeal swab.

Time: 7 days following intervention.

Description: Variation of serum lymphocyte counts during treatment.

Measure: Variation of serum lymphocyte counts.

Time: 7 days following intervention.

Description: Variation of serum AST/ALT values during treatment.

Measure: Variation of serum AST/ALT values.

Time: 7 days following intervention.

Description: Variation of serum D-dimer values during treatment.

Measure: Variation of serum D-dimer values.

Time: 7 days following intervention.

Description: Variation of serum CPK values during treatment.

Measure: Variation of serum CPK values.

Time: 7 days following intervention.

Description: Variation of serum LDH values during treatment.

Measure: Variation of serum LDH values.

Time: 7 days following intervention.

Description: Time to clinical improvement, defined as the time to normalize fever, respiratory rate and oxygen saturation and cough relief in at least 72 hours;

Measure: Time to clinical improvement

Time: 7 days following intervention.

14 Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19

Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of ivermectin for the treatment of initial infection with SARS-CoV2 infection. Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days (I_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient ambulatory care as well as at home, according to routine procedures of recruiting centres. In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.

NCT04438850 Covid19 Drug: Ivermectin Other: Placebo

Primary Outcomes

Description: Number of serious adverse drug reaction

Measure: SADR

Time: 14 days

Description: Quantitative viral load as measured by quantitative, digital droplet PCR.

Measure: Viral load

Time: Assessed at day 7

Secondary Outcomes

Description: 1. Trend over time of quantitative viral load at Day 7 and 14 as measured by quantitative, digital droplet PCR.

Measure: Trend viral load

Time: Days 7 and 14 from baseline

Description: Time to clinical resolution (for symptomatic patients).

Measure: Clinical resolution

Time: Assessed on Day 30

Description: Time from diagnosis to documented viral clearance

Measure: Viral clearance

Time: assessed on days 14 and 30

Description: Proportion of patients with virological clearance

Measure: Virological clearance

Time: Assessed at day 14 and 30

Description: rate of hospitalization

Measure: hospitalization rate

Time: Day 30

Description: COVID-19 Severity Score (Coronavirus Diseases 19 Severity Score) - min value 1 ("no limitation of activities), max value 8 ("death"). Higher scores mean worse outcome

Measure: Severity score

Time: Assessed at Day 14 and Day 30

15 Use of Ivermectin as a Therapeutic Option for Patients With COVID-19

confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

NCT04445311 COVID Drug: Ivermectin

Primary Outcomes

Description: duration from day 1 symptoms till 3 days without symptoms

Measure: time to be symptoms free

Time: within 21 days after enrollment

Secondary Outcomes

Description: need hospital admission

Measure: hospitalization

Time: within 21 days after enrollement

Description: need mechanical ventilation

Measure: Mechanical ventilation

Time: within 21 days after enrollement

Description: days spent in hospital

Measure: length of stay

Time: within one month days after enrollement

Description: survived or died

Measure: mortality

Time: within one month days after enrollement

16 Anti-Androgen Treatment for COVID-19

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

NCT04446429 COVID-19 SARS-CoV2 Androgenetic Alopecia Prostate Cancer Benign Prostatic Hyperplasia SARS (Severe Acute Respiratory Syndrome) Drug: Dutasteride Drug: Ivermectin Drug: Azithromycin Drug: Proxalutamide
MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Prostatic Hyperplasia Alopecia Hyperplasia
HPO:Alopecia Alopecia of scalp Benign prostatic hyperplasia Frontal balding

Primary Outcomes

Description: Percentage of subjects hospitalized due to COVID-19

Measure: COVID-19 hospitalization

Time: 30 days

Description: COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)

Measure: COVID-19 Ordinal Outcomes Scale

Time: 30 days

Secondary Outcomes

Description: Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm

Measure: Symptoms severity of COVID-19

Time: 30 days

17 Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19

Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19

NCT04447235 Cancer COVID Coronavirus Infection Drug: Placebo Drug: Ivermectin Drug: Losartan
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Incidence of severe complications due COVID-19 infection defined as need for ICU admission, need for mechanical ventilation, or death

Measure: Incidence of severe complications due COVID-19 infection

Time: 28 days

Secondary Outcomes

Description: Severe Acute Respiratory Syndrome defined as oxygen saturation less than 93%

Measure: Incidence of Severe Acute Respiratory Syndrome

Time: 28 days

Description: Severe Acute Respiratory Syndrome defined as respiratory rate higher than 24 incursion per minute

Measure: Incidence of Severe Acute Respiratory Syndrome

Time: 28 days

Description: Incidence of hepatic toxicity (elevation of ALT, AST above the upper limit of normal, measured by U/L)

Measure: Adverse events

Time: 28 days

Description: Incidence of hepatic toxicity (elevation of bilirubin above the upper limit of normal, measured by mg/dL)

Measure: Adverse events

Time: 28 days

Description: Incidence of renal toxicity (elevation of serum creatinine levels above the upper limit of normal, measured by mg/dL)

Measure: Adverse events

Time: 28 days

Description: Incidence of symptomatic postural hypotension, diagnosed by clinical assessment of reduction of > 20 mmHG of arterial systolic pressure after measurement in prone position and orthostatic position.

Measure: Adverse events

Time: 28 days

Description: Death of any cause since protocol enrollment

Measure: Overall survival

Time: 28 days

18 Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study

On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.

NCT04460547 COVID-19 Drug: Convalescent Plasma Transfusion Drug: Hydroxychloroquine Drug: DAS181 Drug: Ivermectin Drug: Interferon Beta-1A

Primary Outcomes

Description: To understand the geographical distribution of the interventional studies after 11th of March 2020.

Measure: Geographical distribution of the interventional studies after 11th of March 2020.

Time: 15th of August 2020

Description: To understand the geographical distribution of the Observational studies after 11th of March 2020.

Measure: Geographical distribution of the Observational studies after 11th of March 2020.

Time: 15th of August 2020

Description: To understand the monthly Research study completion rate as per geographic distribution of the Research.

Measure: Monthly Research study completion rate as per geographic distribution of the Research.

Time: 15th of August 2020

Secondary Outcomes

Description: To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the interventional studies Research with developed, developing and under developed countries.

Time: 15th of August 2020

Description: To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the observational studies Research with developed, developing and under developed countries.

Time: 15th of August 2020

Description: To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

Time: 15th of August 2020

Description: To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

Time: 15th of August 2020

Description: To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

Time: 15th of August 2020


Related HPO nodes (Using clinical trials)


HP:0001596: Alopecia
Genes 287
PLEC APCDD1 KLHL24 EDARADD MPLKIP RAG1 FGFR1 ARHGAP31 NOP10 TERT KRT81 LSS TP63 LAMA3 PNPLA6 ERCC5 PADI3 ALMS1 HR KRAS SLC39A4 MBTPS2 FLI1 PORCN LAMA3 RAG2 PKP1 GTF2H5 WRAP53 SLC29A3 DMXL2 FZD2 HLCS GNA11 DSG4 LMNA ATR HFE ARHGAP31 KRT81 UROS TTC7A NSDHL XPC RHOA DSP SMARCA2 AEBP1 MBTPS2 LSS GJB6 HRAS ROR2 LMNA ABCD1 EPS8L3 RIPK4 GTF2E2 GJA1 RNF113A RPL21 ZNF341 KDM5C NXN MGP PLEC VDR CD28 LIG4 SNRPE EDNRA DOCK6 IL7R GJB2 FTL COL7A1 IKBKG CLDN1 HTRA1 CERS3 TINF2 COL3A1 DSG4 NRAS ALOXE3 SOX18 NRAS MBTPS2 MBTPS2 DLL4 NFKB2 NFKB2 IKBKG RIPK4 SLC39A4 FGFR1 KRT14 PEX7 ADA KRAS AHSG COL17A1 PTPN22 LAMB3 UROD RBPJ GJB6 ABHD5 RTEL1 HLA-DRA GJB6 ABHD5 KRT86 OFD1 CTLA4 HFE MMP1 SPP1 DCAF17 EXOSC2 DCAF17 DSP UBR1 TINF2 EBP DCLRE1C TP63 MBTPS2 FAM111B KRT85 PORCN ALOXE3 TGM1 SLITRK1 HR CSTB HLCS ACVR1 SASH1 KRT16 COL17A1 TP63 XPA ERCC3 LIPH RAG2 ZMPSTE24 ALOX12B HFE OFD1 LAMC2 DSP DVL1 LMNA FOXN1 LMNA KRT83 RNU4ATAC PNPLA1 ANTXR1 NPM1 STAT4 KRT86 AIRE AIRE RMRP TP63 PRKACA UQCRFS1 HR FOXN1 ERCC3 HRAS ACVR1 VDR JUP TRPV3 NOTCH1 DMPK DKC1 BTD RBM28 SNRPE LAMC2 BCS1L DVL3 BTNL2 NECTIN1 GJB4 EBP COL7A1 TGM1 GJB3 MMP1 ERCC2 LMNA GJB2 ECM1 RBM28 CHD7 IRAK1 ABCA12 TERC NECTIN4 CD28 CASR IL7R KRT17 TERT TARS1 IL2RG ALMS1 BMP2 KRAS NFKB1 COL18A1 DDB2 TINF2 WNT5A TRPV3 ALX4 PARN EOGT FOXP3 KDM5C AHSG WNT10A KDSR RIN2 SOX18 PIK3R1 GJB2 TERC GJA1 ERCC2 DCLRE1C CTLA4 STUB1 AP1B1 ITGB4 IL2RA TGM1 NIPAL4 PERP NHP2 HLA-DRB1 LMNA ALX4 CLDN1 ZMPSTE24 KRT74 EDAR KRT83 BTK USB1 ZMPSTE24 MBTPS2 LAMB3 TGM3 ERCC4 KRT6B ECM1 BTD BCS1L CTC1 LPAR6 MCCC2 ITGB6 KRT6A GJA1 RECQL4 HR EPS8L3 TNFRSF1B COL7A1 DKC1 ANTXR1 WNT10A TP63 RAG1 SLC30A2 ITGB4 COL3A1 TNFRSF1B SOX18 ALOX12B PARN
Protein Mutations 0
SNP 0